Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical Cord Blood Transplant in Haematological Diseases
NCT02310997Phase 2
Key facts
- Status
- Terminated
- Start
- Jul 2011
- Primary completion
- May 2015
- Countries
- 1
- Sponsor
- University College London
- Modality
- Hematopoietic Stem Cells
- Drugs
- umbilical cord blood
- Conditions
- leukemialymphomamyelodysplastic syndrome (MDS)
01
Overview
Phase 2, open-label trial of umbilical cord blood in leukemia, lymphoma and myelodysplastic syndrome (MDS), sponsored by University College London. Primary endpoint: Non-relapse mortality at 100 days. Started Jul 2011; status: terminated.
02
Design
- Study design
- Non-randomizedOpen-label
03
Who it enrols
Patients aged 4 weeks to 45 years with high-risk haematological diseases, no matched donor, and adequate organ function.
04
Endpoints
Primary
Non-relapse mortality
Secondary
Overall Survival
Donor Chimerism
Hematologic Recovery
Incidence of Acute and Chronic GVHD
Incidence of Relapse
Beyond the preview
Go deeper on NCT02310997.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02310997.